Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Many patients with major depressive disorder have treatment-resistant depression, defined as no adequate response to two consecutive courses of antidepressants. Some evidence suggests that antiglucocorticoid augmentation of antidepressants might be efficacious in patients with major depressive disorder. We aimed to test the proof of concept of metyrapone for the augmentation of serotonergic antidepressants in the clinically relevant population of patients with treatment-resistant depression.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Psychiatry

Title: The lancet. Psychiatry

ISSN (Electronic): 2215-0374

ISSN (Print): 2215-0366

Publication date (Electronic): Feb 2016

Volume: 3

Issue: 2

Affiliations

[1 ] Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK; Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK. Electronic address: r.h.mcallister-williams@ncl.ac.uk.

[2 ] Neuroscience and Psychiatry Unit, Manchester University, Manchester, UK.

[3 ] Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK; Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.

[4 ] Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.

[5 ] Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK; Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK; Department of Psychiatry and Psychotherapy, Paracelsus Medical University, Salzburg, Austria.

[6 ] Neuroscience and Psychiatry Unit, Manchester University, Manchester, UK; Greater Manchester West Mental Health NHS Foundation Trust, Manchester, UK.

[7 ] Leeds and York Partnership NHS Foundation Trust, Leeds, UK.

[8 ] Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK.

[9 ] Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.

[10 ] Bradford District Care NHS Foundation Trust, Bradford, UK; Institute of Health Sciences, University of Leeds, Leeds, UK.

[11 ] Tees, Esk and Wear Valleys NHS Foundation Trust, Darlington, UK.

Article

Publisher Item ID: S2215-0366(15)00436-8

DOI: 10.1016/S2215-0366(15)00436-8

PubMed ID: 26727041

SO-VID: 61c13648-35f4-479c-b547-7ef1a0f92450

History

Data availability:

Comments

Comment on this article

scite_

Cited by 15

See all cited by

- Version 1